CYTOSORBENTS CORPORATION (CTSO) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 2.29M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -12.93M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $2.29M | $-12.93M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $2.49M | $-13.90M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $2.77M | $-14.75M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $2.80M | $-14.09M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $3.20M | $-16.06M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $3.62M | $-16.02M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $3.76M | $-16.79M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $9.72M | (m) | $3.19M | $-22.08M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $11.61M | (m) | $3.49M | $-25.10M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $13.76M | (m) | $3.23M | $-28.24M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $15.73M | (m) | $3.33M | $-31.21M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $15.03M | (m) | $3.36M | $-28.22M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $14.58M | (m) | $3.28M | $-29.82M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $15.09M | (m) | $3.47M | $-31.62M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $15.12M | (m) | $3.42M | $-31.52M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $17.85M | (m) | $3.35M | $-34.73M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $18.83M | (m) | $3.34M | $-31.12M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $18.34M | (m) | $4.14M | $-27.68M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $16.38M | (m) | $4.02M | $-22.74M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $12.93M | (m) | $3.87M | $-15.82M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $10.42M | (m) | $3.96M | $-12.37M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $9.13M | (m) | $3.45M | $-10.74M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $8.81M | (m) | $3.51M | $-10.37M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $9.68M | (m) | $3.36M | $-13.17M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $11.11M | (m) | $3.07M | $-16.84M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $11.64M | (m) | $2.17M | $-17.17M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $12.09M | (m) | $1.67M | $-18.97M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $10.96M | (m) | $2.75M | $-19.13M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $9.72M | $23.25M | $2.22M | $-16.21M | (m) | 41.79% | 9.55% | (m) | (m) |
| 2019-03-31 | $8.42M | $22.77M | $4.14M | $-16.77M | (m) | 36.96% | 18.18% | (m) | (m) |
| 2018-12-31 | $7.72M | $22.50M | $4.44M | $-15.58M | (m) | 34.32% | 19.72% | (m) | (m) |
| 2018-09-30 | $7.79M | $21.07M | $4.33M | $-13.80M | (m) | 36.99% | 20.53% | (m) | (m) |
| 2018-06-30 | $6.49M | $19.15M | $5.01M | $-13.24M | (m) | 33.91% | 26.17% | (m) | (m) |
| 2018-03-31 | $5.36M | $16.96M | $3.75M | $-11.39M | (m) | 31.60% | 22.08% | (m) | (m) |
| 2017-12-31 | $4.05M | $15.15M | $3.31M | $-9.84M | (m) | 26.73% | 21.87% | (m) | (m) |
| 2017-09-30 | $3.29M | $13.59M | $3.88M | $-10.61M | (m) | 24.22% | 28.58% | (m) | (m) |
| 2017-06-30 | $3.79M | $12.18M | $3.05M | $-10.60M | (m) | 31.15% | 25.03% | (m) | (m) |
| 2017-03-31 | $4.40M | $10.83M | $2.74M | $-10.96M | (m) | 40.59% | 25.32% | (m) | (m) |
| 2016-12-31 | $4.78M | $9.53M | $2.76M | $-11.49M | (m) | 50.21% | 28.93% | (m) | (m) |
| 2016-09-30 | $4.37M | $8.21M | $846.08K | $-9.58M | (m) | 53.29% | 10.31% | (m) | (m) |
| 2016-06-30 | $4.07M | $7.14M | $835.62K | $-9.59M | (m) | 56.98% | 11.71% | (m) | (m) |
| 2016-03-31 | $3.78M | $5.88M | $425.79K | $-9.13M | (m) | 64.23% | 7.24% | (m) | (m) |
| 2015-12-31 | $3.87M | $4.79M | $382.28K | $-9.30M | (m) | 80.79% | 7.98% | (m) | (m) |
| 2015-09-30 | $3.59M | $3.90M | $805.80K | $-9.93M | (m) | 91.87% | 20.64% | (m) | (m) |
| 2015-06-30 | $3.60M | $3.72M | $737.41K | $-9.26M | (m) | 96.71% | 19.81% | (m) | (m) |
| 2015-03-31 | $3.15M | $3.78M | $702.05K | $-8.84M | (m) | 83.15% | 18.55% | (m) | (m) |
| 2014-12-31 | $2.43M | $4.12M | $695.84K | $-7.28M | (m) | 58.98% | 16.88% | (m) | (m) |
| 2014-09-30 | $1.50M | $4.13M | (m) | $-5.23M | (m) | 36.25% | (m) | (m) | (m) |
| 2014-06-30 | $910.40K | $3.85M | (m) | $-4.42M | (m) | 23.67% | (m) | (m) | (m) |
| 2014-03-31 | $1.27M | $3.11M | (m) | $-4.45M | (m) | 40.84% | (m) | (m) | (m) |
| 2013-12-31 | $1.74M | $2.42M | (m) | $-4.71M | (m) | 71.78% | (m) | (m) | (m) |
| 2013-09-30 | $2.38M | $2.15M | (m) | $-4.52M | (m) | 111.02% | (m) | (m) | (m) |
| 2013-06-30 | $2.55M | (m) | (m) | $-4.24M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $2.60M | (m) | (m) | $-3.85M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $2.53M | $1.34M | (m) | $-3.49M | (m) | 188.58% | (m) | (m) | (m) |
| 2012-09-30 | $2.35M | $774.69K | (m) | $-3.65M | (m) | 303.23% | (m) | (m) | (m) |
| 2012-06-30 | $2.58M | (m) | (m) | $-4.27M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $2.77M | (m) | (m) | $-4.38M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $2.89M | $36.08K | (m) | $-4.44M | (m) | 8005.56% | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $1.76M | (m) | (m) | $-2.82M | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |